Filing Details

Accession Number:
0001181431-13-060014
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-11-20 19:31:18
Reporting Period:
2013-11-20
Filing Date:
2013-11-20
Accepted Time:
2013-11-20 19:31:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1416792 Relypsa Inc RLYP Pharmaceutical Preparations (2834) 260893742
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1171005 Jonathan Silverstein C/O Orbimed Advisors Llc
601 Lexington Avenue
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-11-20 1,904,940 $0.00 1,904,940 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2013-11-20 1,905,702 $0.00 3,810,642 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2013-11-20 3,007,297 $0.00 6,817,939 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2013-11-20 693,991 $0.00 7,511,930 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2013-11-20 1,417,578 $0.17 8,929,508 No 4 M Indirect See Footnotes
Common Stock Disposition 2013-11-20 22,166 $11.00 8,907,342 No 4 F Indirect See Footnotes
Common Stock Acquisiton 2013-11-20 327,133 $0.17 9,234,475 No 4 M Indirect See Footnotes
Common Stock Disposition 2013-11-20 5,116 $11.00 9,229,359 No 4 F Indirect See Footnotes
Common Stock Acquisiton 2013-11-20 712,192 $11.00 9,941,551 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 M Indirect See Footnotes
No 4 F Indirect See Footnotes
No 4 M Indirect See Footnotes
No 4 F Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B-1 Preferred Stock Disposition 2013-11-20 1,295,845 $0.00 1,904,940 $0.00
Common Stock Series B-2 Preferred Stock Disposition 2013-11-20 1,905,702 $0.00 1,905,702 $0.00
Common Stock Series C-1 Preferred Stock Disposition 2013-11-20 3,007,297 $0.00 3,007,297 $0.00
Common Stock Series C-2 Preferred Stock Disposition 2013-11-20 693,991 $0.00 693,991 $0.00
Series C-1 Preferred Stock Warrant to Purchase Preferred Stock Disposition 2013-11-20 1,417,578 $0.00 1,417,578 $0.17
Common Stock Warrant to Purchase Common Stock Acquisiton 2013-11-20 1,417,578 $0.00 1,417,578 $0.17
Common Stock Warrant to Purchase Common Stock Disposition 2013-11-20 1,417,578 $0.00 1,417,578 $0.17
Series C-2 Preferred Stock Warrant to Purchase Preferred Stock Disposition 2013-11-20 327,133 $0.00 327,133 $0.17
Common Stock Warrant to Purchase Common Stock Acquisiton 2013-11-20 327,133 $0.00 327,133 $0.17
Common Stock Warrant to Purchase Common Stock Disposition 2013-11-20 327,133 $0.00 327,133 $0.17
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 2013-11-20 No 4 J Indirect
1,417,578 2013-11-20 No 4 J Indirect
0 2013-11-20 No 4 M Indirect
0 2013-11-20 No 4 J Indirect
327,133 2013-11-20 No 4 J Indirect
0 2013-11-20 No 4 M Indirect
Footnotes
  1. Reflects a 1-for-17.2 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
  2. Each share of Series B-1 Preferred Stock automatically converted into the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering, at a conversion ratio of 1.47 shares of Common Stock for every 1 share of Series B-1 Preferred Stock.
  3. Shares are directly beneficially owned by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the sole general partner of OPI IV. OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP IV. Samuel D. Isaly ("Isaly") is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP IV, Advisors and Isaly may be deemed to have voting and investment power over the securities beneficially owned by OPI IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a member of Advisors and is obligated to transfer any shares issued under any equity grants made to him by the Issuer to Advisors and certain of its related entities.
  4. Each of the Reporting Person, GP IV, Advisors and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of them are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  5. Each share of Series B-2 Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  6. Each share of Series C-1 Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  7. Each share of Series C-2 Preferred Stock automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
  8. Shares disposed of in connection with net share settlement of outstanding warrants, which resulted in the cancellation of underlying shares to the Issuer, and which did not involve any sale of shares.
  9. The shares did not have an expiration date.
  10. Immediately prior to the closing of the Issuer's initial public offering, this warrant to purchase shares of Series C-1 Preferred Stock automatically converted on a 1-for-1 basis into a warrant to purchase shares of Common Stock. Disposition of Warrant to Purchase Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.
  11. Immediately prior to the closing of the Issuer's initial public offering, this warrant to purchase shares of Series C-2 Preferred Stock automatically converted on a 1-for-1 basis into a warrant to purchase shares of Common Stock. Disposition of Warrant to Purchase Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.